of the tumor. The treatment is complicated by molecular heterogeneity within the histological subtypes and by the lack of prognostic biomarkers. STS clinical management requires a more profound knowledge of the metastatic potential of the tumor. Different biomarkers have been reported that could predict a patient's outcome, but unfortunately the analysis of biomarkers is often time consuming, and it is limited by the insufficient sample (biopsy material); a prompt diagnosis and prediction of metastatic potential is crucial in the management of this type of tumors. In this study, we aimed to combine molecular imaging approaches, with sophisticated imaging analysis and biomarker expression previously reported, in highly metastatic tumors to better predict metastatic capacity of STS in adult patients. Materials/Methods: We report data from a pilot prospective study in 10 STS patients imaged with FDG-PET/CT for cellular metabolism and (18) F-fluoromisonidazole (FMISO) for tissue hypoxia. The patients were imaged before radiation therapy (RT), in the middle of RT, and following RT. The images were analyzed for first order statistics of FDG and FMISO uptakes (mean, SD, skewness, and kurtosis). For biomarker analysis, we obtained tissue sections from the biopsy and resected tumor; mRNA was extracted from 3-8 pieces of 10-mm sections of formalin-fixed, paraffinembedded (FFPE) samples. Gene expression of HIF1A, CD44, CD133, ABCG2, TGFb1 was detected qRT-PCR using the DDCt method.
Purpose/Objective(s): Angiosarcoma is an aggressive soft tissue sarcoma for which there is limited consensus on treatment recommendations given the rare nature of the disease. We examined disease course and evaluated predictors for improved clinical outcomes in a cohort of angiosarcoma patients. Materials/Methods: We conducted a retrospective review of 63 patients treated at our institution for angiosarcoma between 2000 and 2015.
Outcome metrics included overall survival, progression-free survival, time to recurrence, and prognostic factors for survival. Results: Twenty-eight men and 35 women with a median age of 65 (range, 21-87) years were treated for angiosarcoma, of which 75% were primary sarcomas and 25% were secondary (from prior radiation). The most common angiosarcoma sites were breast/chest (nZ21, 33%), head/neck (nZ18, 29%), and extremity (nZ11, 17%), and a majority of patients had grade 3 disease (54%). Initial treatment included surgery in 79% of patients, chemotherapy in 38% (docetaxel+gemcitabine most common), and radiation in 33% (median dose 54 Gy, range 30-72 Gy). Forty-one percent of patients had surgery alone, 25% surgery followed by adjuvant therapy (chemotherapy, radiation, or both), 13% neoadjuvant therapy followed by surgery, 16% chemotherapy and/or radiation without surgery, and 5% no treatment. Almost half (46%) of patients experienced locoregional or distant recurrences, and half of these patients experienced multiple recurrences. The majority of initial recurrences (62%) were locoregional, while 38% were distant. The median time to recurrence from initial treatment was 9.4 months. R0 resection (PZ0.028) and chemotherapy given as part of initial treatment (PZ0.045) were associated with fewer recurrences. Median progression-free survival from initial treatment was 14.6 months (range, 0.5-122.0 months), and median overall survival (OS) from initial diagnosis was 43.8 months (range, 0.5-171.8 months). Improved OS was seen in patients with breast/chest angiosarcoma (median 84.6 months vs 39.6 months for head/neck and 12.7 months for extremity, PZ0.008), those with secondary angiosarcoma (median 81.7 months vs 32.2 months for primary sarcoma, PZ0.024), and patients treated with surgery followed by adjuvant therapy (median 74.3 months vs 39.6 months for surgery alone, 14 months for treatments without surgery, and 2.4 months for no treatment, PZ0.002). Conclusion: Frequent recurrences after initial therapy are observed in patients with angiosarcoma. However, surgery followed by adjuvant therapy improves overall survival. Combined modality therapy including surgical resection and chemotherapy should be utilized to treat patients with this aggressive malignancy. Purpose/Objective(s): The gold standard for treatment of early-stage nonmelanoma skin cancers (NMSC) is surgery. For certain anatomical structures, such as the nose and ear, definitive surgery is difficult because it fails to achieve a good cosmetic result with negative margins. In these situations radiation therapy is the preferred treatment. We have used a modern version of brachytherapy, the "3D topographic applicator brachytherapy" (3TAB), to treat NMSC since 2010. This study retrospectively analyzes NMSC lesions of the ear and nose treated with 3TAB in terms of acute toxicity, chronic toxicity, and recurrence rate. Materials/Methods: Seventy-four patients with 88 early-stage NMSC lesions of the ear and nose were treated with 3TAB from 2010-2013. For each lesion, a custom applicator was created using a thermoplastic mold with HAM or Feiburg flap. A 3D optimized plan was created to prescribe the dose to a 3-mm depth. Dose fractionation schemes included 40 Gy in 8 fractions (fxs) delivered 2 times per week, or 48 Gy in 16 fxs delivered 4 times per week. Acute toxicity was graded by RTOG criteria. Chronic toxicity was graded by the presence or lack of toxicity. Results: Outlined in Table 1 , 68.2% of NMSC were located on the nose. Of all lesions, 76.1% were basal cell carcinomas, and 8% were recurrent disease. In all, 88.6% of NMSC were stage I, and median tumor diameter was 0.96 cm (mean: 0.8 cm; range: 0.3-4.5 cm). In total, 98.9% completed treatment, and 86.4% were treated with 40 Gy in 8 fxs. Median follow-up was 24.9 months (mean: 25.6; range: 0-60.1 months). Acute toxicity was 36.4% for grade 1, 60.2% for grade 2, and 3.4% for grade 3. Recurrence rate was 4.6%, and time to recurrence was 20.2 months (median 16.0, range 3.4-45.7). Chronic toxicities occurred in 9 pts; erythema in 7 (8.0%), telangiectasia in 2 (2.3%), skin retraction in 1 (1.1%), and hypopigmentation in 1 (1.1%).
reviewed in the framework of the Rare Cancer Network. Patients who had surgery alone were compared with patients who received surgery (S) and postoperative RT (pRT) or RT alone. Local control (LC), disease-free survival (DFS), and overall survival (OS) were calculated with Kaplan-Meier method and the differences by log-rank test. Final results will include univariate and multivariate analysis. Results: Out of 92 pts, 55 were female (60%) and 37 were male (40%), with a median age of 52 years (range, 18-82). Anatomical locations included head and neck (24%), thorax (23%), pelvis (20%), spine (13%), extremities (9%), retroperitoneum (6%), and abdomen (5%). Fifty-two (57%) pts underwent S alone, 31 pts (34%) S and pRT, and 9 pts (9%) RT alone. Gross total surgical removal was performed in 81% of the 83 pts who underwent surgery (S alone: 85%; S and pRT: 75%) and subtotal removal in 19% (S alone: 15%; S and pRT: 25%). Postoperative RT was administered to a median total dose of 50 Gy (range 45-66) with fractionation of 1.8-2.2 Gy. RT alone was delivered to a median total dose of 55 Gy (range 24-64 Gy), with 2-4 Gy/fraction. After median follow-up of 4 years (range, 1.5-7 years), 65/92 pts (71%) were alive, 26 pts (29%) were dead, and 1 pt was lost. Local recurrence (LR) occurred in 38% of the pts (35/92): 52% after S alone, 20% after S and pRT, and 50% after RT alone. In 50% of the cases treated by RT, LR was "in field." Actuarial LC rate at 3 and 5 years were 80% and 73%, respectively. The 5-year OS and DFS rates were 81% and 64%, respectively. In the group of 83 pts who underwent S, the 5-year LC, OS, and DFS rates were 67% and 85% (PZ0.01), 90% and 76% (PZ0.54), and 59% and 74% (PZ0.09), respectively, for those who received S alone and for those who received S and pRT. Conclusion: This study shows that S is the main treatment modality of extracranial HPC/SFT and pRT was used in less than 50% of the patients. Despite the relatively lower percentage of total surgical excisions, local control was significantly higher in pts treated with S and pRT than in those who received S alone. Purpose/Objective(s): Treatment-induced pathologic necrosis has been demonstrated to be a predictor for both local recurrence and overall survival (OS) in high-grade extremity soft tissue sarcoma (STS). The purpose of this study was to determine if texture analysis of magnetic resonance (MR) images following neoadjuvant therapy (NT) for STS could be used to identify pathologic responders to treatment. Materials/Methods: The medical records of 36 consecutive patients with STS who completed preoperative external beam radiation therapy (EBRT) between 2009 and 2015 were reviewed. T2-weighted MR images obtained prior to any treatment and following NT prior to surgery were analyzed. Images were analyzed using various texture analysis algorithms including Gray-level co-occurrence matrix (GLCM) texture analysis to extract texture features using a fixed volume in each imaging sequence. Analysis of adjacent normal skeletal muscle was used for image normalization. The association between each of the texture measures and pathologic necrosis percent were assessed by the Spearman correlation method and the difference in texture measures between patients with and without 95% pathologic necrosis was tested by Wilcoxon 2-sample tests. Results: Thirty-six patients were included in this study, 35 treated at initial presentation and 1 with recurrent disease. Twenty-two men and 14 women were included with a median age of 57 years (range, 19-83). STS tumor 
